Trial Profile
A Double Blind, Randomized and Placebo Controlled Ascending Single Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ASP1707 in Healthy Young Japanese Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Opigolix (Primary)
- Indications Endometriosis; Prostate cancer
- Focus Adverse reactions
- Sponsors Astellas Pharma Europe Ltd
- 06 Jun 2014 New trial record